Home | By sponsor

CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title Date of Registration State
Nimotuzumab inoperable esophageal epithelial tumors, Phase IV 30/06/2016 Registered
Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC) 30/04/2018 Registered
Nimotuzumab-pancreatic cancer-adults-Phase IV. 30/04/2017 Registered
Predictor of response with CIMAvax EGF© in NSCLC Phase III 29/01/2016 Registered
Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT) 28/12/2018 Registered
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer 28/11/2016 Registered
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. 26/05/2014 Registered
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus 23/12/2016 Registered
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. 23/05/2014 Registered
hR3 in metastatic or recurrent colorectal cancer 22/11/2013 Registered
CIMAvax-EGF in patients at high risk of lung cancer 22/10/2020 Registered
Itolizumab for Relapsing Remitting Multiple Sclerosis 22/05/2015 Registered
NAcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-II 22/04/2016 Registered
EGF vaccine- Advanced Lung tumors 2013-06-20 Registered
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors 2013-06-19 Registered
T1h in severe psoriasis-expanded access program (PUCE) 2012-07-20 Registered
h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin. 2010-12-29 Registered
NAcGM3/VSSP/Montanide ISA 51 formulation in HIV, phase II. 2010-12-29 Registered
Patients with non small cells lung cancer (NSCLC) and brain metastasis. 2010-12-29 Registered
hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma. 2010-12-29 Registered